Literature DB >> 32094504

TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity.

Qiaoshi Lian1, Shanshan Yan1,2, Qi Yin1,3, Chenghua Yan1, Wanwei Zheng4, Wangpeng Gu1,2, Xinhao Zhao1, Weiguo Fan1, Xuezhen Li1, Liyan Ma1, Zhiyang Ling1, Yaguang Zhang5, Jie Liu6,7, Jinsong Li8, Bing Sun9.   

Abstract

Loss of the colonic inner mucus layer leads to spontaneously severe colitis and colorectal cancer. However, key host factors that may control the generation of the inner mucus layer are rarely reported. Here, we identify a novel function of TRIM34 in goblet cells (GCs) in controlling inner mucus layer generation. Upon DSS treatment, TRIM34 deficiency led to a reduction in Muc2 secretion by GCs and subsequent defects in the inner mucus layer. This outcome rendered TRIM34-deficient mice more susceptible to DSS-induced colitis and colitis-associated colorectal cancer. Mechanistic experiments demonstrated that TRIM34 controlled TLR signaling-induced Nox/Duox-dependent ROS synthesis, thereby promoting the compound exocytosis of Muc2 by colonic GCs that were exposed to bacterial TLR ligands. Clinical analysis revealed that TRIM34 levels in patient samples were correlated with the outcome of ulcerative colitis (UC) and the prognosis of rectal adenocarcinoma. This study indicates that TRIM34 expression in GCs plays an essential role in generating the inner mucus layer and preventing excessive colon inflammation and tumorigenesis.

Entities:  

Keywords:  Colon inflammation; Goblet cell; Muc2; TRIM34; Toll-like receptor

Mesh:

Substances:

Year:  2020        PMID: 32094504      PMCID: PMC8027410          DOI: 10.1038/s41423-020-0366-2

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   22.096


  56 in total

Review 1.  Ulcerative colitis.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Cancers complicating inflammatory bowel disease.

Authors:  Laurent Beaugerie; Steven H Itzkowitz
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

Review 4.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

Authors:  Natalie A Molodecky; Ing Shian Soon; Doreen M Rabi; William A Ghali; Mollie Ferris; Greg Chernoff; Eric I Benchimol; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Gilaad G Kaplan
Journal:  Gastroenterology       Date:  2011-10-14       Impact factor: 22.682

Review 5.  The pharmacoeconomics of biologic therapy for IBD.

Authors:  Russell D Cohen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

6.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 7.  Optimizing the safety of biologic therapy for IBD.

Authors:  Shanika de Silva; Shane Devlin; Remo Panaccione
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

8.  Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia.

Authors:  Siew C Ng; Zhirong Zeng; Ola Niewiadomski; Whitney Tang; Sally Bell; Michael A Kamm; Pinjin Hu; H Janaka de Silva; Madunil A Niriella; W S A A Yasith Udara; David Ong; Khoon Lin Ling; Choon Jin Ooi; Ida Hilmi; Khean Lee Goh; Qin Ouyang; Yu Fang Wang; Kaichun Wu; Xin Wang; Pises Pisespongsa; Sathaporn Manatsathit; Satimai Aniwan; Julajak Limsrivilai; Jeffri Gunawan; Marcellus Simadibrata; Murdani Abdullah; Steve W C Tsang; Fu Hang Lo; Aric J Hui; Chung Mo Chow; Hon Ho Yu; Mo Fong Li; Ka Kei Ng; Jessica Y L Ching; Victor Chan; Justin C Y Wu; Francis K L Chan; Minhu Chen; Joseph J Y Sung
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

9.  Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study.

Authors:  Siew C Ng; Whitney Tang; Jessica Y Ching; May Wong; Chung Mo Chow; A J Hui; T C Wong; Vincent K Leung; Steve W Tsang; Hon Ho Yu; Mo Fong Li; Ka Kei Ng; Michael A Kamm; Corrie Studd; Sally Bell; Rupert Leong; H Janaka de Silva; Anuradhani Kasturiratne; M N F Mufeena; Khoon Lin Ling; Choon Jin Ooi; Poh Seng Tan; David Ong; Khean L Goh; Ida Hilmi; Pises Pisespongsa; Sathaporn Manatsathit; Rungsun Rerknimitr; Satimai Aniwan; Yu Fang Wang; Qin Ouyang; Zhirong Zeng; Zhenhua Zhu; Min Hu Chen; Pin Jin Hu; Kaichun Wu; Xin Wang; Marcellus Simadibrata; Murdani Abdullah; Justin Cy Wu; Joseph J Y Sung; Francis K L Chan
Journal:  Gastroenterology       Date:  2013-04-09       Impact factor: 22.682

Review 10.  Origin and physiological roles of inflammation.

Authors:  Ruslan Medzhitov
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

View more
  4 in total

1.  Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.

Authors:  Shichuan Tan; Ryan Spear; Juan Zhao; Xiulian Sun; Pin Wang
Journal:  Front Genet       Date:  2022-06-27       Impact factor: 4.772

2.  STIM1 Deficiency In Intestinal Epithelium Attenuates Colonic Inflammation and Tumorigenesis by Reducing ER Stress of Goblet Cells.

Authors:  Xiaojing Liang; Jiansheng Xie; Hao Liu; Rongjie Zhao; Wei Zhang; Haidong Wang; Hongming Pan; Yubin Zhou; Weidong Han
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-03-31

Review 3.  Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions.

Authors:  Rirong Chen; Yizhe Tie; Jinyu Lu; Li Li; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Cell Prolif       Date:  2022-04-04       Impact factor: 8.755

Review 4.  The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe?

Authors:  Min Zou; Qi-Shan Zeng; Jiao Nie; Jia-Hui Yang; Zhen-Yi Luo; Hua-Tian Gan
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.